ATE172642T1 - Impfstoffe und verfahren zu ihrer herstellung - Google Patents

Impfstoffe und verfahren zu ihrer herstellung

Info

Publication number: ATE172642T1
Authority: AT; Austria
Prior art keywords: virus; vaccines; production; methods; treating
Prior art date: 1991-05-17

Application number

AT92304422T

Other languages

English (en)

Inventor

John Sidney Oxford

Original Assignee

Retroscreen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-17

Filing date

1992-05-15

Publication date

1998-11-15

1992-05-15 Application filed by Retroscreen Ltd filed Critical Retroscreen Ltd

1998-11-15 Application granted granted Critical

1998-11-15 Publication of ATE172642T1 publication Critical patent/ATE172642T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
241000700605 Viruses Species 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 2
230000000415 inactivating effect Effects 0.000 abstract 2
229940124718 AIDS vaccine Drugs 0.000 abstract 1
239000003431 cross linking reagent Substances 0.000 abstract 1
239000003599 detergent Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
230000003019 stabilising effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
- C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Telephone Function (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AT92304422T 1991-05-17 1992-05-15 Impfstoffe und verfahren zu ihrer herstellung ATE172642T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB919110808A GB9110808D0 (en)	1991-05-17	1991-05-17	Aids vaccine and method for its production

Publications (1)

Publication Number	Publication Date
ATE172642T1 true ATE172642T1 (de)	1998-11-15

Family

ID=10695252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92304422T ATE172642T1 (de)	1991-05-17	1992-05-15	Impfstoffe und verfahren zu ihrer herstellung

Country Status (16)

Country	Link
US (1)	US5698432A (de)
EP (1)	EP0514199B1 (de)
JP (1)	JPH05328967A (de)
KR (1)	KR0149182B1 (de)
AT (1)	ATE172642T1 (de)
AU (1)	AU652447B2 (de)
BR (1)	BR9201848A (de)
CA (1)	CA2068817A1 (de)
DE (1)	DE69227400T2 (de)
ES (1)	ES2127203T3 (de)
GB (1)	GB9110808D0 (de)
IE (1)	IE921556A1 (de)
IN (1)	IN174080B (de)
NZ (1)	NZ242780A (de)
SG (1)	SG49763A1 (de)
ZA (1)	ZA923607B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69131427T2 (de) *	1991-05-28	1999-11-25	Kabushiki Kaisha Toshiba, Kawasaki	Arbeitsvorrichtung
AUPN030794A0 (en)	1994-12-22	1995-01-27	Aruba International Pty Ltd	Discontinuous plasma or serum delipidation
DE19520216C2 (de) *	1995-06-01	1997-04-10	Frey Rainer H	Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung
US20040053208A1 (en) *	1995-08-29	2004-03-18	V. I. TECHNOLOGIES, Inc.	Methods to selectively inactivate parasites in biological compositions
US6352695B1 (en)	1997-10-03	2002-03-05	V.I. Technologies, Inc.	Methods and compositions for the selective modification of nucleic acids
US6093564A (en) *	1997-10-03	2000-07-25	V.I. Technologies, Inc.	Methods and compositions for the selective modification of nucleic acids
US6617100B2 (en)	1998-09-25	2003-09-09	V.I. Technologies, Inc.	Solid phase quenching systems
US6403359B1 (en)	1998-09-25	2002-06-11	V. I. TECHNOLOGIES, Inc.	Solid phase quenching systems
DE19916085A1 (de) *	1998-10-28	2000-05-04	Sonntag Hans Guenther	Verfahren zur Herstellung eines antiviralen Mittels
US6649170B1 (en) *	1999-05-12	2003-11-18	Statens Serum Institut	Adjuvant combinations for immunization composition and vaccines
TR200202104T2 (tr) *	1999-12-20	2002-12-23	Agricultural Research Council	Mikroorganizmaların etkisiz hale getirilmesi yöntemi.
US20090017069A1 (en)	2000-06-29	2009-01-15	Lipid Sciences, Inc.	SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) *	2000-06-29	2000-07-27	Aruba International Pty Ltd	A vaccine
US7407662B2 (en) *	2000-06-29	2008-08-05	Lipid Sciences, Inc.	Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en)	2000-06-29	2008-10-21	Lipid Sciences	Method of making modified immunodeficiency virus particles
US7407663B2 (en) *	2000-06-29	2008-08-05	Lipid Sciences, Inc.	Modified immunodeficiency virus particles
US6991727B2 (en)	2001-06-25	2006-01-31	Lipid Sciences, Inc.	Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en)	2001-06-25	2006-03-23	Bomberger David C	Systems and methods using a solvent for the removal of lipids from fluids
WO2003000381A1 (en)	2001-06-25	2003-01-03	Lipid Sciences, Inc.	Hollow fiber contactor systems for removal of lipids from fluids
DE10144906B4 (de) *	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003048366A1 (en) *	2001-12-07	2003-06-12	Postech Foundation	Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
JP2007527387A (ja)	2003-07-03	2007-09-27	リピッドサイエンシーズ，インコーポレイテッド	脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US7393826B2 (en)	2003-07-03	2008-07-01	Lipid Sciences, Inc.	Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP5535910B2 (ja) *	2007-08-28	2014-07-02	バクスター・インターナショナル・インコーポレイテッド	ウイルスワクチンを生産する方法
EP2566958B1 (de)	2010-05-03	2015-12-30	GlaxoSmithKline Biologicals S.A.	Verfahren zur inaktivierung des influenza-virus
EP2855513B1 (de) *	2012-06-01	2016-12-07	Boehringer Ingelheim Vetmedica GmbH	Schmallenberg-virus (sbv)-impfstoff, verfahren zur herstellung und verwendung
EP2858722B8 (de)	2012-06-08	2018-02-21	Aduro BioTech, Inc.	Zusammensetzungen und verfahren zur krebsimmuntherapie
SG11201502796RA (en)	2012-12-13	2015-05-28	Aduro Biotech Inc	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016524593A (ja)	2013-04-29	2016-08-18	メモリアルスローン−ケタリングキャンサーセンター	セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh)	2013-05-03	2019-11-12	加利福尼亚大学董事会	I型干扰素的环状二核苷酸诱导
CU24377B1 (es)	2013-05-18	2018-12-05	Aduro Biotech Inc	Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (de)	2013-05-18	2019-03-27	Aduro Biotech, Inc.	Zusammensetzungen und verfahren zur hemmung einer vom interferon-gen-stimulator unabhängigen signalisierung
US10176292B2 (en)	2013-07-31	2019-01-08	Memorial Sloan-Kettering Cancer Center	STING crystals and modulators
JP5865942B2 (ja)	2014-04-16	2016-02-17	三菱電機株式会社	内燃機関のシリンダ吸入空気量推定装置および推定方法
TWI706958B (zh)	2015-03-10	2020-10-11	美商艾杜諾生物科技公司	活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
EP3507367A4 (de)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JP7550448B2 (ja)	2017-11-22	2024-09-13	エイチディーエルセラピューティクスインコーポレイテッド	血漿処理システムの流体回路をプライミングするシステムおよび方法
AU2018396009A1 (en)	2017-12-28	2020-07-16	Hdl Therapeutics, Inc.	Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
WO2019143955A1 (en)	2018-01-22	2019-07-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly protective inactivated influenza virus vaccine
US11643641B2 (en) *	2021-03-04	2023-05-09	Malireddy S. Reddy	Prevention of viral transmission by naked genetic material

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1617457A1 (de) *	1966-12-16	1972-04-20	Erba Carlo Spa	Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US4036952A (en) *	1973-02-24	1977-07-19	Bayer Aktiengesellschaft	Ethyleneimine inactivated microorganisms
DE2321951C2 (de) *	1973-05-02	1975-05-07	Behringwerke Ag, 3550 Marburg	Verfahren zur Herstellung einer Diphtherie-Vaccine
US4086134A (en) *	1973-09-18	1978-04-25	University Of Glasgow	Method for preparation of vaccine against feline leukemia
GB1503388A (en) *	1975-07-01	1978-03-08	Inverni Della Beffa Spa	Pharmaceutically active complexes and pharmaceutical compositions containing them
US4452734A (en) *	1980-02-11	1984-06-05	Merck & Co., Inc.	Herpes subunit vaccine
US4481189A (en) *	1982-04-14	1984-11-06	New York Blood Center Inc.	Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) *	1982-06-08	1987-02-24	The Regents Of The University Of California	Vaccine for bluetongue disease employing platinum compounds
US4530831A (en) *	1982-11-02	1985-07-23	Akzo N.V.	Infectious Bursal Disease vaccine
US4806350A (en) *	1986-04-18	1989-02-21	Norden Laboratories, Inc.	Vaccine formulation
EP0250128A3 (de) *	1986-06-18	1988-06-08	American Registry of Pathology	Von AIDS-Patienten isoliertes Virus
DE3707987A1 (de) *	1987-03-12	1988-09-22	Behringwerke Ag	Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
GB8906794D0 (en) *	1989-03-23	1989-05-10	Carroll Noel	Preparation of vaccines

1991
- 1991-05-17 GB GB919110808A patent/GB9110808D0/en active Pending
1992
- 1992-05-15 CA CA002068817A patent/CA2068817A1/en not_active Abandoned
- 1992-05-15 EP EP92304422A patent/EP0514199B1/de not_active Expired - Lifetime
- 1992-05-15 DE DE69227400T patent/DE69227400T2/de not_active Expired - Fee Related
- 1992-05-15 AT AT92304422T patent/ATE172642T1/de not_active IP Right Cessation
- 1992-05-15 SG SG1996004956A patent/SG49763A1/en unknown
- 1992-05-15 BR BR929201848A patent/BR9201848A/pt not_active Application Discontinuation
- 1992-05-15 ES ES92304422T patent/ES2127203T3/es not_active Expired - Lifetime
- 1992-05-15 IN IN294MA1992 patent/IN174080B/en unknown
- 1992-05-15 AU AU16340/92A patent/AU652447B2/en not_active Ceased
- 1992-05-18 JP JP4168187A patent/JPH05328967A/ja active Pending
- 1992-05-18 NZ NZ24278092A patent/NZ242780A/en not_active IP Right Cessation
- 1992-05-18 KR KR1019920008346A patent/KR0149182B1/ko not_active Expired - Fee Related
- 1992-05-18 ZA ZA923607A patent/ZA923607B/xx unknown
- 1992-07-01 IE IE155692A patent/IE921556A1/en not_active IP Right Cessation
1996
- 1996-10-11 US US08/729,135 patent/US5698432A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69227400T2 (de)	1999-07-01
AU1634092A (en)	1992-12-17
DE69227400D1 (de)	1998-12-03
SG49763A1 (en)	1998-06-15
US5698432A (en)	1997-12-16
EP0514199B1 (de)	1998-10-28
NZ242780A (en)	1994-07-26
IE921556A1 (en)	1992-11-18
KR920021162A (ko)	1992-12-18
ZA923607B (en)	1993-02-24
BR9201848A (pt)	1993-01-05
EP0514199A2 (de)	1992-11-19
EP0514199A3 (en)	1993-11-10
IN174080B (de)	1994-09-10
KR0149182B1 (ko)	1998-10-15
AU652447B2 (en)	1994-08-25
ES2127203T3 (es)	1999-04-16
CA2068817A1 (en)	1992-11-18
GB9110808D0 (en)	1991-07-10
JPH05328967A (ja)	1993-12-14

Legal Events

Date	Code	Title
1999-08-15	UEP	Publication of translation of european patent specification
2001-09-15	EEIH	Change in the person of patent owner
2008-02-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69227400D1 (de)	1998-12-03	Impfstoffe und Verfahren zu ihrer Herstellung
DE3486160D1 (de)	1993-07-15	Modifizierte lebende pseudo-rabies-viren, diese enthaltende impfstoffe gegen pseudo-rabies, verfahren zur herstellung und verfahren zur verwendung derselben.
ATE257175T1 (de)	2004-01-15	Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
DE69434820D1 (de)	2006-09-21	Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
PT97754A (pt)	1992-04-30	Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus
ZA979732B (en)	1998-05-22	Infectious clones of RNA viruses and vaccines and diagnostic assays derived therof.
CY1107720T1 (el)	2013-04-18	Ιος συνδρομου πολυσυστηματικης απισχνανσεως μετα τον απογαλακτισμο απο χοιρους
ATE528406T1 (de)	2011-10-15	Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer
ATE217144T1 (de)	2002-05-15	Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
ATE369435T1 (de)	2007-08-15	Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen
DE3684255D1 (de)	1992-04-16	Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
ATE106748T1 (de)	1994-06-15	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
EP0755440A4 (de)	1998-08-19	Mutierte viren, anti-virale verbindungen und methoden zur herstellung von impfstoffen
ATE317019T1 (de)	2006-02-15	Rekombinanter vektor, der infektiöse virale genomsequenzen mit einer grösse von mehr als 100 kb enthält, verfahren zu seiner herstellung und verwendung
ATE187496T1 (de)	1999-12-15	Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
ATE193726T1 (de)	2000-06-15	Spezifische nukleotidsequenz enthaltender masernvirusvakzinstamm und verfahren zu seiner absoluten identifizierung
ATE16454T1 (de)	1985-11-15	Influenzavirus-vaccine, verfahren zu ihrer herstellung und verfahren zur vermehrung von influenzaviren.
DE59303465D1 (de)	1996-09-26	Verfahren zur Reaktivierung eines bei der Herstellung von 1,1,1,2,3,3,3-Heptafluorpropan (R 227) eingesetzten Aktivkohle-Katalysators
DE69324645D1 (de)	1999-06-02	Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
PT85093A (fr)	1987-07-01	Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
DE69203192D1 (de)	1995-08-03	Verfahren zur Herstellung von N-Ethylhydroxylamin-Hydrochlorid.
DE60035680D1 (de)	2007-09-06	Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
DE69916763D1 (de)	2004-06-03	Verfahren zur Herstellung von wärmebehandelten, sprühgegossesen Superlegierungsgegenstände
DE50104531D1 (de)	2004-12-23	Verfahren zum Dauerwellen von menschlichen Haaren
CY1116153T1 (el)	2017-02-08	Ιος συνδρομου πολυσυστηματικης απισχνανσεως μετα τον απογαλακτισμο απο χοιρους